Do Outcomes of Meniscal Allograft Transplantation Differ Based on Age and Sex? A Comparative Group Analysis.


Journal

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association
ISSN: 1526-3231
Titre abrégé: Arthroscopy
Pays: United States
ID NLM: 8506498

Informations de publication

Date de publication:
02 2022
Historique:
received: 08 10 2020
revised: 06 05 2021
accepted: 12 05 2021
pubmed: 31 5 2021
medline: 11 3 2022
entrez: 30 5 2021
Statut: ppublish

Résumé

To analyze the effect of patient age, sex, and associated preoperative factors on patient-reported outcome (PRO) measures and graft survival following primary meniscal allograft transplantation (MAT). A prospectively collected database was retrospectively reviewed to identify patients who underwent primary MAT with a minimum of 2 years of follow up between 1999 and 2017. Demographic, intraoperative, and postoperative outcome data were collected for each patient. Postoperative outcomes were stratified based on age and sex, and comparative statistical analysis was performed between sexes, both >40 and <40. A total of 238 patients underwent primary MAT during the study period, of which 212 patients (mean age, 28.5 ± 9.0 years; range, 15.01-53.67 years) met the inclusion criteria with a mean follow-up of 5.1 ± 3.4 years (range 2.0-15.9 years). At final follow-up, patients ≥40 and <40 years of age demonstrated statistically significant improvements in nearly all PRO scores (P < .05 for both groups). There were no significant differences between either group for achievement of minimal clinically important difference for International Knee Documentation Committee (P = .48) or Knee Injury and Osteoarthritis Outcome Score symptoms (P = .76). Because of insufficient numbers, a statistically significant difference could not be demonstrated in reoperation rate (≥40: 1.49 ± 1.77 years, <40: 1.87 ± 1.98 years, P = .591), failure rate (≥40: 7/32 [21.9%], <40: 19/180 [10.6%], P = .072), or complication rate (≥40: 2/32 [6.3%], <40: 12/180 [6.7%], P = .930) based on age. Both sexes showed a significant improvement in PROs, whereas female patients were more likely to undergo revision surgery (P = .033), with no significant differences based on time to reoperation, failure, or complication rates. PROs similarly improved following MAT in both patients aged ≥40 and those <40 at final follow-up with no significant differences in minimal clinically important difference achievement rate, complication rate, reoperation rate, time to reoperation, or failure rate between groups. Female patients may be more likely to undergo revision surgery after MAT. III; therapeutic retrospective comparison study.

Identifiants

pubmed: 34052385
pii: S0749-8063(21)00515-6
doi: 10.1016/j.arthro.2021.05.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

452-465.e3

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Rachel Frank (R)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Ron Gilat (R)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Eric D Haunschild (ED)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Hailey Huddleston (H)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Sumit Patel (S)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Aghogho Evuarherhe (A)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Derrick M Knapik (DM)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Justin Drager (J)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Adam B Yanke (AB)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.

Brian J Cole (BJ)

Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, Illinois, U.S.A.. Electronic address: brian.cole@rushortho.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH